Growth along with consent of the host-dependent, PDL1-independent, biomarker to calculate 6-month progression-free survival inside metastatic non-small cellular cancer of the lung (mNSCLC) people treated with anti-PD1 resistant gate inhibitors (ICI) from the CERTIM Cohort: Your ELY examine.